FindTrial
Sign In

Pharmacogenomics and determination of serum steroids in the research progress of personalized medication in congenital adrenal hyperplasia

Pharmacogenomics and determination of serum steroids in the research progress of personalized medication in congenital adrenal hyperplasia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034908
Enrollment
Unknown
Registered
2020-07-24
Start date
2018-01-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital adrenal hyperplasia

Interventions

Case series:no

Sponsors

Capital Institute of Pediatrics
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 13 Years

Inclusion criteria

Inclusion criteria: According to the 3rd edition of pediatrics (editor-in-chief by GUI Yonghao and Xue Xindong, People's Medical Publishing House, 2015), the patient was diagnosed with congenital adrenal hyperplasia by comprehensive clinical manifestations and laboratory examination and took glucocorticoids regularly.

Exclusion criteria

Exclusion criteria: Patients who are taking drugs or foods that may affect the enzyme activity during treatment, such as phenytoin, rifampicin, clarithromycin, itraconazole, ketoconazole, erythromycin, verapamil, cimetidine, diltiazem, fluconazole, grapefruit juice, and those failing to sign the informed consent,and those unwilling or unable to perform inspection requirements.

Design outcomes

Primary

MeasureTime frame
Height;Weight;serum steroids;biochemistry;boneage;gene;—

Countries

China

Contacts

Public ContactChen Xiao-Bo

Capital Institute of Pediatrics

xiaobochen6362@163.com+86 13681094823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026